Breaking News

Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts

Breaking: MedPAC Staff Unable to Link Higher Drug Spending at 340B Hospitals to Incentives Created by 340B Discounts

Medicare Payment Advisory Commission (MedPAC) researchers were “unable to attribute” evidence of higher drug spending at 340B hospitals on two types of

Read More »

MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs

MedPAC Will Weigh in on Whether 340B Causes Hospitals to Use More Expensive Drugs

The Medicare Payment Advisory Commission (MedPAC) will hear from its staff on Jan. 17 about whether the 340B program gives participating hospitals an incentive to

Read More »

Breaking News

BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says

BREAKING: States Can Limit Providers’ Use of 340B Drugs for Medicaid Patients, CMS Says

The Centers for Medicare & Medicaid Services released policy guidance yesterday outlining “best practices” states should consider for avoiding duplicate Medicaid rebates and 340B discounts

Read More »

Breaking News

BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus

BREAKING: HRSA Awards 340B Prime Vendor Agreement to Apexus

The Health Resources and Services Administration (HRSA) announced this morning that it has awarded the 340B Prime Vendor Agreement to Apexus LLC after a competitive bid process.

“The 340B Prime Vendor

Read More »

Breaking News

BREAKING: Drugmaker Xspire Owes 340B Refunds

Greetings

Welcome to the pilot issue of 340B Report. We’re so glad to have you aboard! And now, let’s get to the news.

BREAKING: Drugmaker Xspire Owes 340B Refunds

Xspire Pharma, a privately held, specialty pharmaceutical company, owes refunds

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report